HeartWare International

HeartWare International Inc. of Framingham said it received a warning letter following an inspection by the U.S. Food and Drug Administration (FDA) at its developing and manufacturing facility in Miami Lakes, Fla.

Fueled by sales of it its Ventricular Assist Systems, Framingham-based HeartWare International on Thursday announced a 35-percent jump in revenue for the first quarter, from $49.2 million in the first quarter of 2013 to $66.5 million.

Framingham-based HeartWare International reissued a warning Thursday regarding serious issues with its Ventricular Assist System, which aids people with advanced stage heart failure. The company said it has received eight complaints of failed locking mechanisms in the patient driveline connection, which connect the device to an external controller used to power and monitor the device.

Thanks largely to its first year of its heart disease treatment being sold commercially, Framingham-based HeartWare International saw its revenue rise more than 60 percent in the fourth quarter, but fell short of analyst expectations, as the company had warned last month.

HeartWare International said Tuesday that its fourth-quarter revenue may fall short of market expectations.

HeartWare International of Framingham has bought a New Jersey-based medical device manufacturer in a deal that could wind up being worth $350 million.

Revenue soared and losses narrowed at HeartWave International of Framingham due to rising sales of its Ventricular Assist System.

Continuing to ride high on the commercial launch of its Ventricular Assist System, HeartWare International, which makes technologies that treat heart disease, saw its revenue and profits soar in the second quarter.

The stock of medical device manufacturer HeartWare International of Framingham is being delisted from the Australian Securities Exchange at the company's request, HeartWare said.